Immunotherapy combo for liver cancer before transplant shows promise but study halted
NCT ID NCT05027425
First seen May 15, 2026 · Last updated May 18, 2026 · Updated 1 time
Summary
This study tested two immunotherapy drugs, durvalumab and tremelimumab, in 8 people with liver cancer who were waiting for a liver transplant. The goal was to see if the drugs could safely control the cancer and reduce the risk of organ rejection after transplant. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Simmons Comprehensive Cancer Center UT Southwestern Medical Center
Dallas, Texas, 75235, United States
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
Washington University School of Medicine
St Louis, Missouri, 63130, United States
Conditions
Explore the condition pages connected to this study.